---
figid: PMC11347096__nihms-2007498-f0006
figtitle: Schematic diagram summarizes the potential therapeutic targets of different
  lipid species and related pathways to treat inflammatory disease or B cell malignancy
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11347096
filename: nihms-2007498-f0006.jpg
figlink: /pmc/articles/PMC11347096/figure/F6
number: F6
caption: The schematic diagram summarizes the potential therapeutic targets of different
  lipid species and related pathways to treat inflammatory disease or B cell malignancy.
  Multiple studies have demonstrated promising immunomodulatory or therapeutic effects
  of small molecules targeting different layers of lipid metabolism in B cells. Combined
  treatment with FDA-approved small molecules and drugs for B cell malignancies such
  as imatinib, ibrutinib, dacinostat, CAL-101, and T-5224 can produce synergistic
  effects, enhancing therapeutic efficacy and offering a broader array of strategies
  for personalized treatment. All the figures were generated using biorender.com
papertitle: Leveraging altered lipid metabolism in treating B cell malignancies
reftext: Jaewoong Lee, et al. Prog Lipid Res. 2024 Jul 17;95(NA).
year: '2024'
doi: 10.1016/j.plipres.2024.101288
journal_title: Progress in lipid research
journal_nlm_ta: Prog Lipid Res
publisher_name: .na.character
keywords: Lipid metabolism | B cell malignancy | Leukemia | Lymphoma | B cell receptor
  | Obese
automl_pathway: 0.9211606
figid_alias: PMC11347096__F6
figtype: Figure
redirect_from: /figures/PMC11347096__F6
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11347096__nihms-2007498-f0006.html
  '@type': Dataset
  description: The schematic diagram summarizes the potential therapeutic targets
    of different lipid species and related pathways to treat inflammatory disease
    or B cell malignancy. Multiple studies have demonstrated promising immunomodulatory
    or therapeutic effects of small molecules targeting different layers of lipid
    metabolism in B cells. Combined treatment with FDA-approved small molecules and
    drugs for B cell malignancies such as imatinib, ibrutinib, dacinostat, CAL-101,
    and T-5224 can produce synergistic effects, enhancing therapeutic efficacy and
    offering a broader array of strategies for personalized treatment. All the figures
    were generated using biorender.com
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FASLG
  - CD79A
  - BCR
  - RN7SL263P
  - TLR1
  - TLR2
  - TLR3
  - TLR4
  - TLR5
  - TLR6
  - TLR7
  - TLR8
  - TLR9
  - TLR10
  - MBTPS1
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - SFTA3
  - S1PR1
  - S1PR2
  - S1PR3
  - S1PR4
  - S1PR5
  - SPHK1
  - SPHK2
  - FAS
  - FASN
  - KRAS
  - HRAS
  - NRAS
  - FDPS
  - FES
  - PTPA
  - MAPK8
  - MAPK9
  - MAPK10
  - UGCG
  - BTK
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MTOR
  - MYC
  - HDAC1
  - HDAC2
  - FOS
  - AKT1
  - AKT2
  - AKT3
  - CPT1A
  - CPT2
  - CHPT1
  - ATP8A2
  - CDKN1B
  - NFKB1
  - S1P
  - Imatinib
  - Sph
  - FTY720
  - Nucleus
  - Cholesterol
  - RAS
  - acid
  - Ceramide
  - Everolimus
  - Orlistat
  - Fatty acid
  - HMG-CoA
---
